MCID: EPT010
MIFTS: 48

Epithelial-Myoepithelial Carcinoma

Categories: Rare diseases, Oral diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Epithelial-Myoepithelial Carcinoma

MalaCards integrated aliases for Epithelial-Myoepithelial Carcinoma:

Name: Epithelial-Myoepithelial Carcinoma 12 76 53 29 15 40 73
Clear Cell Adenoma 53 73
Epithelial Myoepithelial Carcinoma 53
Glycogen-Rich Adenocarcinoma 53
Monomorphic Clear Cell Tumor 53
Adenocarcinoma, Clear Cell 73
Glycogen-Rich Adenoma 53
Tubular Solid Adenoma 53
Adenomyo-Epithelioma 53
Clear Cell Carcinoma 53
Emc 53

Classifications:



External Ids:

Disease Ontology 12 DOID:5309
NCIt 50 C4199
SNOMED-CT 68 189722008 9618003
UMLS 73 C0334392

Summaries for Epithelial-Myoepithelial Carcinoma

MalaCards based summary : Epithelial-Myoepithelial Carcinoma, also known as clear cell adenoma, is related to pleomorphic adenoma and chondrosarcoma, extraskeletal myxoid. An important gene associated with Epithelial-Myoepithelial Carcinoma is NR4A3 (Nuclear Receptor Subfamily 4 Group A Member 3), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Pathways Affected in Adenoid Cystic Carcinoma. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, lung and kidney, and related phenotypes are Decreased CDKN1A mRNA expression and Decreased CDKN1A mRNA expression

Wikipedia : 76 Epithelial-myoepithelial carcinoma, abbreviated EMCa, is a rare malignant tumour that typically arises... more...

Related Diseases for Epithelial-Myoepithelial Carcinoma

Diseases related to Epithelial-Myoepithelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 pleomorphic adenoma 31.1 HMGA2 KRT14 TP53
2 chondrosarcoma, extraskeletal myxoid 30.2 NR4A3 SMARCB1 TAF15
3 papillary adenocarcinoma 29.5 KRT7 TP53
4 adenoid cystic carcinoma 29.5 FBXW7 HRAS KRT14 KRT7 TP53
5 ovarian clear cell carcinoma 12.4
6 parathyroid transitional clear cell adenoma 12.3
7 clear cell adenoma 12.3
8 water-clear cell adenoma 12.3
9 thymus clear cell carcinoma 12.1
10 hepatocellular clear cell carcinoma 12.0
11 lung clear cell carcinoma 12.0
12 clear cell renal cell carcinoma 11.7
13 clear cell adenocarcinoma 11.5
14 myoepithelioma 11.1
15 endometrial clear cell adenocarcinoma 11.0
16 fallopian tube clear cell adenocarcinoma 11.0
17 cervical clear cell adenocarcinoma 11.0
18 bile duct clear cell adenocarcinoma 11.0
19 multilocular cystic renal neoplasm of low malignant potential 11.0
20 malignant ectomesenchymoma 10.8 HMGA2 HRAS
21 benign breast adenomyoepithelioma 10.8 KRT14 KRT7
22 ectomesenchymoma 10.8 HMGA2 HRAS
23 large cell acanthoma 10.8 KRT14 KRT7
24 oncocytic breast carcinoma 10.8 KRT14 KRT7
25 apocrine sweat gland neoplasm 10.8 KRT14 KRT7
26 cervical adenoma malignum 10.7 HMGA2 KRT7
27 brooke-spiegler syndrome 10.7 KRT14 KRT7
28 cervical mucinous adenocarcinoma 10.7 HMGA2 KRT7
29 anal canal adenocarcinoma 10.7 HRAS KRT7
30 spitz nevus 10.7 HRAS TP53
31 breast squamous cell carcinoma 10.7 KRT14 TP53
32 breast adenomyoepithelioma 10.7 KRT14 KRT7
33 breast myoepithelial neoplasm 10.7 KRT14 KRT7
34 ampulla of vater neoplasm 10.7 HRAS KRT7
35 well-differentiated liposarcoma 10.7 HMGA2 KRT7
36 malignant spiradenoma 10.7 KRT7 TP53
37 female reproductive endometrioid cancer 10.7 KRT7 TP53
38 scrotal carcinoma 10.7 HMGA2 TP53
39 eccrine sweat gland neoplasm 10.7 KRT7 TP53
40 breast benign neoplasm 10.7 KRT14 TP53
41 thoracic benign neoplasm 10.7 KRT14 TP53
42 meningeal melanomatosis 10.6 HRAS TP53
43 bladder carcinoma in situ 10.6 KRT7 TP53
44 papillary serous adenocarcinoma 10.6 KRT7 TP53
45 esophageal basaloid squamous cell carcinoma 10.6 KRT14 TP53
46 dedifferentiated liposarcoma 10.6 HMGA2 TP53
47 glycogen-rich clear cell breast carcinoma 10.6 KRT7 TP53
48 immune system organ benign neoplasm 10.6 HMGA2 KRT7
49 thymus lipoma 10.6 HMGA2 KRT7
50 pleomorphic carcinoma 10.6 KRT7 TP53

Graphical network of the top 20 diseases related to Epithelial-Myoepithelial Carcinoma:



Diseases related to Epithelial-Myoepithelial Carcinoma

Symptoms & Phenotypes for Epithelial-Myoepithelial Carcinoma

GenomeRNAi Phenotypes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased CDKN1A mRNA expression GR00389-S-1 9.63 TP53 FBXW7
2 Decreased CDKN1A mRNA expression GR00389-S-2 9.63 TP53 HMGA2
3 Increased proliferation GR00094-A 8.96 SMARCB1 TP53
4 Increased TP53 mRNA expression GR00389-S-6 8.62 HMGA2 TP53

MGI Mouse Phenotypes related to Epithelial-Myoepithelial Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.92 PLIN1 PLIN2 SMARCB1 FBXW7 TP53 HRAS
2 homeostasis/metabolism MP:0005376 9.91 PLIN1 PLIN2 SMARCB1 FBXW7 TP53 HRAS
3 integument MP:0010771 9.7 PLIN1 PLIN2 FBXW7 TP53 HRAS KRT14
4 liver/biliary system MP:0005370 9.43 PLIN1 PLIN2 SMARCB1 FBXW7 TP53 NR4A3
5 neoplasm MP:0002006 9.1 SMARCB1 FBXW7 TP53 HRAS KRT14 NR4A3

Drugs & Therapeutics for Epithelial-Myoepithelial Carcinoma

Drugs for Epithelial-Myoepithelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Doxil Approved June 1999 Phase 3,Phase 2 31703
7 Topoisomerase Inhibitors Phase 3,Phase 2
8 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
9 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
13
Sunitinib Approved, Investigational Phase 2,Not Applicable 341031-54-7, 557795-19-4 5329102
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
16
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
17
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
18
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
19
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
20
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
21
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
22
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
23
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
24
Nintedanib Approved Phase 2 656247-17-5 56843413
25
nivolumab Approved Phase 2 946414-94-4
26
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
27
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
29
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
30
Trebananib Investigational Phase 2 894356-79-7
31
Tremelimumab Investigational Phase 2 745013-59-6
32 Chelating Agents Phase 2
33 Angiogenesis Inhibitors Phase 2,Not Applicable
34 Angiogenesis Modulating Agents Phase 2,Not Applicable
35 Anticoagulants Phase 2
36 Calcium, Dietary Phase 2
37 Interleukin-2 Phase 2
38 Analgesics Phase 2
39 interferons Phase 2
40 Analgesics, Non-Narcotic Phase 2
41 Histone Deacetylase Inhibitors Phase 2
42 Peripheral Nervous System Agents Phase 2
43 Antibodies Phase 2,Phase 1
44 Immunoglobulins Phase 2,Phase 1
45 Antibodies, Monoclonal Phase 2,Phase 1
46 Immunosuppressive Agents Phase 2,Phase 1
47 Anti-Infective Agents Phase 2,Phase 1
48 Interferon-alpha Phase 2
49 Antifungal Agents Phase 2,Phase 1
50 Anti-HIV Agents Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
3 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
4 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
5 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
6 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
7 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
8 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
9 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
10 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
11 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
12 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
13 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
14 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
15 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
16 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
17 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
18 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
19 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
20 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
21 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
22 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00113373 Phase 2 lapatinib ditosylate
23 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
24 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
25 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
26 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Recruiting NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
27 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Recruiting NCT03066427 Phase 2 Sunitinib
28 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
29 A Study of PLX2853 in Advanced Malignancies. Recruiting NCT03297424 Phase 1, Phase 2 PLX2853
30 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
31 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2 ferumoxtran-10
32 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02315430 Phase 2 Cabozantinib S-malate
33 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2 Dasatinib
34 TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00563784 Phase 2 Erlotinib;Carboplatin;Paclitaxel
35 Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Not yet recruiting NCT03348631 Phase 2 Tazemetostat
36 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
37 ATN-161 in Advanced Renal Cell Cancer Terminated NCT00131651 Phase 2 ATN-161
38 ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer Completed NCT00056537 Phase 1 ABR-217620
39 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
40 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Active, not recruiting NCT02837991 Phase 1 CDX-014
41 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting NCT01625351 Phase 1 alemtuzumab;fludarabine;sirolimus;Busulfan;melphalan
42 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
43 Ovarian Clear Cell Adenocarcinoma Review Completed NCT02129036
44 Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy Completed NCT02282579 Pazopanib
45 The Role of Hypoxia as a Selective Pressure for TP53 Mutations Recruiting NCT03466034
46 Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma Active, not recruiting NCT01582204 Not Applicable 124IcG250
47 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Active, not recruiting NCT01504126 Not Applicable Propranolol;Chemotherapy
48 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Not yet recruiting NCT02774395
49 Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Withdrawn NCT01732432

Search NIH Clinical Center for Epithelial-Myoepithelial Carcinoma

Genetic Tests for Epithelial-Myoepithelial Carcinoma

Genetic tests related to Epithelial-Myoepithelial Carcinoma:

# Genetic test Affiliating Genes
1 Epithelial-Myoepithelial Carcinoma 29 NR4A3 TAF15

Anatomical Context for Epithelial-Myoepithelial Carcinoma

MalaCards organs/tissues related to Epithelial-Myoepithelial Carcinoma:

41
Salivary Gland, Lung, Kidney, Ovary, Tongue, Lymph Node, Breast

Publications for Epithelial-Myoepithelial Carcinoma

Articles related to Epithelial-Myoepithelial Carcinoma:

(show top 50) (show all 192)
# Title Authors Year
1
Sinonasal epithelial-myoepithelial carcinoma: Report of a novel subsite and review of the literature. ( 29977654 )
2018
2
Epithelial-Myoepithelial Carcinoma: Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases. ( 29135520 )
2018
3
The So-Called Aggressive Digital Papillary Adenocarcinoma Is Epithelial-Myoepithelial Carcinoma. ( 29384814 )
2018
4
MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms. ( 29135517 )
2018
5
Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: A case report. ( 29642184 )
2018
6
Epithelial-myoepithelial carcinoma with high-grade transformation of parotid gland: A case report and literature review. ( 29245272 )
2017
7
Epithelial-Myoepithelial Carcinoma of the Base of Tongue with Possible Lung Metastases. ( 29085691 )
2017
8
Endobronchial epithelial-myoepithelial carcinoma of the lung. ( 29196470 )
2017
9
Salivary epithelial-myoepithelial carcinoma: clinical, morphological and molecular features. ( 28635988 )
2017
10
Epithelial Myoepithelial Carcinoma of the Nasal Cavity: Clinical, Histopathological, and Immunohistochemical Distinction of a Case Report. ( 29237344 )
2017
11
First case report of a curative wedge resection in epithelial-myoepithelial carcinoma of the lung. ( 28653299 )
2017
12
Carcinoma Ex Pleomorphic Adenoma of the Lacrimal Gland with Epithelial-Myoepithelial Carcinoma Histologic Type. ( 26934566 )
2016
13
Going beyond "Basaloid neoplasm": Fine needle aspiration cytology of epithelial-myoepithelial carcinoma of the parotid gland. ( 26798976 )
2016
14
A rare case of primary peripheral epithelial myoepithelial carcinoma of lung: Case report and literature review. ( 27583848 )
2016
15
Epithelial-myoepithelial carcinoma of the minor salivary glands: a case report and review of the literature. ( 27599278 )
2016
16
Sinonasal epithelial-myoepithelial carcinoma: A case report. ( 27773082 )
2016
17
Fine-Needle Aspiration of Epithelial-Myoepithelial Carcinoma of the Parotid Gland With Prominent Adenoid Cystic Carcinoma-Like Cribriform Features: Avoiding a Diagnostic Pitfall. ( 27614667 )
2016
18
Epithelial-Myoepithelial Carcinoma of the Salivary Gland Harboring HRAS Codon 61 Mutations With Lung Metastasis. ( 26675036 )
2016
19
Cytomorphologic Attributes of Epithelial Myoepithelial Carcinoma of Nasal Cavity - A Rare Tumor with Unusual Clinical Presentation. ( 27790447 )
2016
20
Epithelial-myoepithelial carcinoma arising from the subglottis: a case report and review of the literature. ( 26922486 )
2016
21
Bilateral epithelial-myoepithelial carcinoma of the parotid glands. ( 26314935 )
2015
22
High-grade epithelial-myoepithelial carcinoma of the parotid gland with mucous cell differentiation. ( 26037059 )
2015
23
Salivary Gland Epithelial-Myoepithelial Carcinoma with High-Grade Transformation in a Dog. ( 26223938 )
2015
24
Nasal epithelial myoepithelial carcinoma: An unusual cause of epiphora, a case report and review of the literature. ( 26302736 )
2015
25
Epithelial-myoepithelial carcinoma of lacrimal gland from an ex pleomorphic adenoma. ( 26231189 )
2015
26
Epithelial-Myoepithelial Carcinoma of the Salivary Glands: An Analysis of 246 Cases. ( 26195572 )
2015
27
A Rare Case of Bronchial Epithelial-Myoepithelial Carcinoma with Solid Lobular Growth in a 53-Year-Old Woman. ( 26508939 )
2015
28
Primary epithelial-myoepithelial carcinoma of the lung: A case report demonstrating high-grade transformation-like changes. ( 26170995 )
2015
29
Endobronchial laser ablation in the management of epithelial-myoepithelial carcinoma of the trachea. ( 26744686 )
2015
30
Parotid epithelial-myoepithelial carcinoma: an unexpected intraoperative finding. ( 25809427 )
2015
31
Global transcriptome and sequenome analysis of formalin-fixed salivary epithelial-myoepithelial carcinoma specimens. ( 25546727 )
2015
32
Tracheal epithelial-myoepithelial carcinoma associated with sarcoid-like reaction: A case report. ( 26029574 )
2015
33
Epithelial-myoepithelial Carcinoma - Review of Clinicopathological and Immunohistochemical Features. ( 25841941 )
2015
34
Epithelial-myoepithelial carcinoma metastasis to the thoracic spine. ( 26474503 )
2015
35
Epithelial-myoepithelial carcinoma of the nasopharynx: A case report and review of the literature. ( 26622597 )
2015
36
Iodine-125 brachytherapy for the treatment of a large parotid epithelial-myoepithelial carcinoma in a child. ( 25240907 )
2014
37
An unusual case of epithelial-myoepithelial carcinoma of the parotid gland radiologically simulating a benign lesion. ( 24959051 )
2014
38
Epithelial-myoepithelial carcinoma of the hypopharynx: A rare case. ( 24932273 )
2014
39
Case study of a parotid gland adenocarcinoma dedifferentiated from epithelial-myoepithelial carcinoma. ( 25276459 )
2014
40
Epithelial-myoepithelial carcinoma of the parotid gland: Clinicopathological aspect, diagnosis and surgical consideration. ( 24987609 )
2014
41
Sebaceous epithelial-myoepithelial carcinoma of the parotid gland: a case report of a new histologic variant. ( 24929841 )
2014
42
Radiation-induced epithelial-myoepithelial carcinoma in a patient previously treated with mantle-field radiation therapy for Hodgkin's Lymphoma. ( 25242451 )
2014
43
Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland. ( 25096657 )
2014
44
Epithelial-myoepithelial carcinoma of the trachea-a rare entity case report. ( 24672694 )
2014
45
Epithelial-myoepithelial carcinoma of floor of mouth: A case report with cytological, histological and immunohistochemical correlation. ( 25937734 )
2014
46
Epithelial-Myoepithelial Carcinoma of the Lacrimal Gland 14 Years After En Bloc Resection of a Pleomorphic Lacrimal Gland Adenoma. ( 25025382 )
2014
47
Cytologic features of sebaceous epithelial-myoepithelial carcinoma of the salivary gland: A brief report of a rare variant. ( 25417919 )
2014
48
Dedifferentiated epithelial-myoepithelial carcinoma of salivary glands. ( 23515555 )
2013
49
Primary epithelial-myoepithelial carcinoma of lung: a case report of a rare salivary gland type tumour. ( 23619585 )
2013
50
Dedifferentiated epithelial-myoepithelial carcinoma: analysis of a rare entity based on a case report and literature review. ( 23222809 )
2013

Variations for Epithelial-Myoepithelial Carcinoma

Cosmic variations for Epithelial-Myoepithelial Carcinoma:

9
(show top 50) (show all 237)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10758 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 33
2 COSM12597 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.3145G>C p.G1049R 3:179234302-179234302 33
3 COSM13570 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.331A>G p.K111E 3:179199156-179199156 33
4 COSM6963776 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 33
5 COSM496 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 33
6 COSM13168 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 33
7 COSM33765 AKT1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.49G>A p.E17K 14:104780214-104780214 33
8 COSM6963774 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 33
9 COSM6963775 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.254T>A p.L85* 23:53217863-53217863 33
10 COSM307275 TP53 salivary gland,NS,carcinoma,myoepithelial carcinoma c.96+1G>T p.? 17:7676381-7676381 32
11 COSM6920823 STAG2 salivary gland,NS,carcinoma,myoepithelial carcinoma c.1808G>A p.G603E 23:124063192-124063192 32
12 COSM27495 PIK3CA salivary gland,NS,carcinoma,myoepithelial carcinoma c.35G>A p.G12D 3:179198860-179198860 32
13 COSM12459 PIK3CA salivary gland,NS,carcinoma,myoepithelial carcinoma c.1637A>G p.Q546R 3:179218307-179218307 32
14 COSM5609465 MTOR salivary gland,NS,carcinoma,myoepithelial carcinoma c.5534A>T p.E1845V 1:11130608-11130608 32
15 COSM21159 MAP2K4 salivary gland,NS,carcinoma,myoepithelial carcinoma c.752G>A p.S251N 17:12113299-12113299 32
16 COSM553 KRAS salivary gland,NS,carcinoma,myoepithelial carcinoma c.182A>T p.Q61L 12:25227342-25227342 32
17 COSM499 HRAS salivary gland,NS,carcinoma,myoepithelial carcinoma c.182A>G p.Q61R 11:533874-533874 32
18 COSM498 HRAS salivary gland,NS,carcinoma,myoepithelial carcinoma c.182A>T p.Q61L 11:533874-533874 32
19 COSM6916641 ATM salivary gland,NS,carcinoma,myoepithelial carcinoma c.4940T>C p.L1647P 11:108297317-108297317 32
20 COSM3717687 salivary gland,NS,carcinoma,myoepithelial carcinoma c.96+1G>T p.? 17:7676381-7676381 32
21 COSM446012 salivary gland,NS,carcinoma,myoepithelial carcinoma c.1637A>G p.Q546R 3:179218307-179218307 32
22 COSM244958 salivary gland,NS,carcinoma,myoepithelial carcinoma c.182A>G p.Q61R 11:533874-533874 32
23 COSM307276 salivary gland,NS,carcinoma,myoepithelial carcinoma c.96+1G>T p.? 17:7676381-7676381 32
24 COSM307277 salivary gland,NS,carcinoma,myoepithelial carcinoma c.96+1G>T p.? 17:7676381-7676381 32
25 COSM6920822 salivary gland,NS,carcinoma,myoepithelial carcinoma c.1808G>A p.G603E 23:124063192-124063192 32
26 COSM307278 salivary gland,NS,carcinoma,myoepithelial carcinoma c.96+1G>T p.? 17:7676381-7676381 32
27 COSM3717686 salivary gland,NS,carcinoma,myoepithelial carcinoma c.96+1G>T p.? 17:7676381-7676381 32
28 COSM6916640 salivary gland,NS,carcinoma,myoepithelial carcinoma c.4940T>C p.L1647P 11:108297317-108297317 32
29 COSM1658946 VWA5B1 salivary gland,parotid,carcinoma,NS c.1486G>A p.V496I 1:20330897-20330897 18
30 COSM5030964 VHL salivary gland,parotid,carcinoma,NS c.319C>T p.R107C 3:10142166-10142166 18
31 COSM1659032 TXNRD3 salivary gland,parotid,carcinoma,NS c.412A>G p.K138E 3:126647293-126647293 18
32 COSM10654 TP53 salivary gland,parotid,carcinoma,NS c.637C>T p.R213* 17:7674894-7674894 18
33 COSM5030953 TP53 salivary gland,parotid,carcinoma,NS c.38C>T p.P13L 17:7676557-7676557 18
34 COSM11564 TP53 salivary gland,parotid,carcinoma,NS c.742C>G p.R248G 17:7674221-7674221 18
35 COSM44850 TP53 salivary gland,parotid,carcinoma,NS c.494A>T p.Q165L 17:7675118-7675118 18
36 COSM43632 TP53 salivary gland,parotid,carcinoma,NS c.493C>T p.Q165* 17:7675119-7675119 18
37 COSM11305 TP53 salivary gland,parotid,carcinoma,NS c.809T>C p.F270S 17:7673811-7673811 18
38 COSM44640 TP53 salivary gland,parotid,carcinoma,NS c.782+1G>T p.? 17:7674180-7674180 18
39 COSM45307 TP53 salivary gland,parotid,carcinoma,NS c.309C>A p.Y103* 17:7676060-7676060 18
40 COSM43687 TP53 salivary gland,parotid,carcinoma,NS c.641A>G p.H214R 17:7674890-7674890 18
41 COSM11196 TP53 salivary gland,parotid,carcinoma,NS c.734G>T p.G245V 17:7674229-7674229 18
42 COSM43814 TP53 salivary gland,parotid,carcinoma,NS c.587G>C p.R196P 17:7674944-7674944 18
43 COSM43596 TP53 salivary gland,parotid,carcinoma,NS c.841G>A p.D281N 17:7673779-7673779 18
44 COSM43918 TP53 salivary gland,parotid,carcinoma,NS c.809T>A p.F270Y 17:7673811-7673811 18
45 COSM10886 TP53 salivary gland,parotid,carcinoma,NS c.310C>T p.Q104* 17:7676059-7676059 18
46 COSM10690 TP53 salivary gland,parotid,carcinoma,NS c.473G>A p.R158H 17:7675139-7675139 18
47 COSM46283 TP53 salivary gland,parotid,carcinoma,NS c.569C>A p.P190H 17:7674962-7674962 18
48 COSM12013 TP53 salivary gland,parotid,carcinoma,NS c.731G>C p.G244A 17:7674232-7674232 18
49 COSM10646 TP53 salivary gland,parotid,carcinoma,NS c.725G>A p.C242Y 17:7674238-7674238 18
50 COSM10704 TP53 salivary gland,parotid,carcinoma,NS c.844C>T p.R282W 17:7673776-7673776 18

Expression for Epithelial-Myoepithelial Carcinoma

Search GEO for disease gene expression data for Epithelial-Myoepithelial Carcinoma.

Pathways for Epithelial-Myoepithelial Carcinoma

Pathways related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.19 HMGA2 NR4A3 TAF15 TP53
2 10.95 FBXW7 HRAS TP53

GO Terms for Epithelial-Myoepithelial Carcinoma

Cellular components related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.32 FBXW7 HMGA2 HRAS KRT14 KRT7 NR4A3

Biological processes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.71 HMGA2 NR4A3 TAF15 TP53
2 intrinsic apoptotic signaling pathway GO:0097193 9.37 HRAS TP53
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.35 HMGA2 HRAS NR4A3 SMARCB1 TP53
4 cell aging GO:0007569 9.32 HRAS TP53
5 positive regulation of cell cycle arrest GO:0071158 9.26 HMGA2 TP53
6 cellular response to gamma radiation GO:0071480 9.16 HRAS TP53
7 viral process GO:0016032 8.92 FBXW7 KRT7 SMARCB1 TP53

Molecular functions related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone acetyltransferase binding GO:0035035 8.62 NR4A3 TP53

Sources for Epithelial-Myoepithelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....